{"groups":[{"description":"CYCLE 1: Patients receive salsalate by mouth daily ( PO BID) until completion of cycle 1. 24-48 hours later or concurrent with salsalate, patients begin to receive decitabine IV for 10 days or azacitidine IV for 7 days. Starting 24 hour after salsalate, patients also receive venetoclax PO continuously until completion of cycle 1.\n\nCYCLE 2: Patients receive decitabine IV for 5 days or azacitidine IV for 7 days, salsalate PO BID, and venetoclax PO continuously.\n\nCycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.\n\nAzacitidine: Given IV\n\nDecitabine: Given IV\n\nSalsalate: Given PO\n\nVenetoclax: Given PO","id":"FG000","title":"Treatment (Salsalate, Decitabine, Azacitidine, Venetoclax)"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"5"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"5"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}